The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Sign Up to like & getrecommendations! Published in 2020 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izaa036
Abstract: BACKGROUND No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. METHODS The Sicilian Prospective Observational Study of Patients With IBD Treated With Infliximab Biosimilar SB2 is a… read more here.
Keywords: sb2; inflammatory bowel; biosimilar sb2; effectiveness ... See more keywords
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Gastroenterology and Nutrition"
DOI: 10.1097/mpg.0000000000003683
Abstract: Objectives: PERFUSE is a non-interventional study of 1233 patients [inflammatory rheumatic disease, n = 496; inflammatory bowel disease (IBD), n = 737] receiving infliximab (IFX) biosimilar SB2 therapy. This analysis describes response to treatment and… read more here.
Keywords: disease; perfuse non; ibd patients; biosimilar sb2 ... See more keywords